Vanguard Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
Other funds holding BCRX
JHC
Vanguard Capital Management's BCRX Position: Q3 2026 in Review
Vanguard Capital Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 0.86% in Q3 2026, selling an estimated $916K and leaving 11,266,982 shares worth $93.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1556.
Vanguard Capital Management first reported a position in BCRX in Q1 2026 and has held it in 3 quarters since. The position peaked at $114M in Q2 2026. 334 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.
- Vanguard Capital Management held 11,266,982 shares of BioCryst Pharmaceuticals worth $93.9M as of Q3 2026.
- Vanguard Capital Management sold 97,254 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $916K.
- BioCryst Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1556 holding.
- Vanguard Capital Management first reported a position in BioCryst Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's BioCryst Pharmaceuticals position peaked at $114M in Q2 2026.
- 334 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.